Medical News
September 10th, 2009
GlaxoSmithKline recently advised the public that the US FDA’s Vaccines and Related Biological Products Advisory Committee voted that Ceravix, the company’s cervical cancer vaccine, presented data that substantiates the efficacy and safety of the treatment.
September 9th, 2009
Recent research argues that long-term subjection to lead may increase the risk of death caused by heart disease.
September 8th, 2009
Ceravix will become the main component in the fight against cervical cancer in developing nations. The World Health Organization (WHO) has granted Cervarix prequalification (GlaxoSmithKlein’s cervical cancer vaccine). This decision will enable UN agencies and GAVI Alliance to purchase and utilize the vaccine in union with developing countries.
September 3rd, 2009
The U.S. FDA warns the public that there is a potential for stolen long-acting insulin Levemir, produced by Novo Nordisk Inc, to still be active on the market. Based on the FDA’s evidence, their proof suggests that the stolen insulin was improperly stored and handled, leaving the public vulnerable to risk. Many patients have informed the FDA of adverse side effects they experienced after using a vial from the stolen group, their glucose levels were incorrectly managed.
September 1st, 2009
In an attempt to manage the evolution of digital media in the healthcare industry, Palio has joined with Zemoga (a full-service interactive agency). This partnership comes as a result of the changing technological environment as well as a result of the changes in consumer abilities and demands.
September 1st, 2009
A recent national survey revealed that a considerable minority of physicians inaccurately
thought that specific off-label uses of prescription medications had been approved by the U.S Food and Drug Administration.
September 1st, 2009
American experts are not convinced that the postponed receipt of the swine flu vaccine will derail the American government’s intention of defending their country against the virus’ recent spread.
